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Abstract
Background: Colorectal cancer (CRC) is the third leading cause of cancer related deaths worldwide both in men
and women. Our recent studies have indicated an association of heat shock protein 70–2 (HSP70-2) with bladder
urothelial carcinoma. In the present study, we investigated the association of HSP70-2 with various malignant
properties of colorectal cancer cells and clinic-pathological features of CRC in clinical specimens.
Methods: HSP70-2 mRNA and protein was investigated expression by RT-PCR, immunohistochemistry,
immunofluorescence, flow cytometry and Western blotting in CRC clinical specimens and COLO205 and HCT116
cell lines. Plasmid-based gene silencing approach was employed to study the association of HSP70-2 with various
malignant properties of COLO205 and HCT116 cells in in vitro and with tumor progression in in vivo COLO205
human xenograft mice model.
Results: HSP70-2 expression was detected in 78 % of CRC patients irrespective of various stages and grades by
RT-PCR and IHC. Our analysis further revealed that HSP70-2 expression was detected in both COLO205 and HCT116
cell lines. Ablation of HSP70-2 expression resulted in reduced cellular growth, colony forming ability, migratory and
invasive ability of CRC cells. In addition, ablation of HSP70-2 expression showed significant reduction in tumor
growth in COLO205 human xenograft in in vivo mouse model.
Conclusion: Collectively, our results indicate that HSP70-2 is associated with CRC clinical specimens. In addition,
down regulation of HSP70-2 expression reduces cellular proliferation and tumor growth indicating that HSP70-2
may be a potential therapeutic target for CRC treatment.
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Background
Colorectal cancer (CRC) is the third leading cause of
cancer related deaths in women and second in men in
developed countries [1]. Colonoscopy remains the gold
standard method for CRC screening till date [2]. CRC
patients diagnosed at early stages (stage I & II) have better
prognosis with the survival rate of 5 years [3]. However,
when diagnosed at later stages (stage III & IV), there are
several treatment options but response rates are low and
recurrence is high [3]. Chemotherapy is the current thera-
peutic option for advanced CRC which has limited efficacy
with poor prognosis [3]. Therefore, there is a need to iden-
tify a tumor associated molecule for developing as a thera-
peutic target for CRC treatment.
Recently, a member of heat shock protein (HSP) pro-
tein family, HSP70-2 has been documented to be asso-
ciated with bladder carcinoma [4], cervical carcinoma
[5], esophageal carcinoma [6] and renal cell carcinoma
[7]. HSP70-2 has been proposed to be a new member of
cancer testis (CT) antigen family. HSP70-2 has been
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shown to be expressed in germ cells in testis during
spermatogenesis and plays an important role in the first
meiotic division of male germ cell and is transcribed from
human chromosome 14q24.1, a region also involved in
alteration of expression of colorectal cancer-related genes
[8]. CT antigens are a unique class of proteins that are
expressed in male germ cells and are also expressed abun-
dantly in various malignancies [9].
In the present study, we assessed HSP70-2 gene and
protein expression in CRC patient specimens. We demon-
strated the involvement of HSP70-2 in various malignant
properties of CRC cell line models by employing plasmid
driven short hairpin RNA (shRNA) interference approach.
Our results showed that HSP70-2 protein is expressed in
majority of the early stages of CRC patients. We further
documented that HSP70-2 plays an important role in
cellular proliferation, migration, and invasion of CRC cells.
Also, HSP70-2 shRNA administration reduces the tumor
growth of human xenograft in in vivo mouse model.
Therefore, HSP70-2 may serve as a potential therapeutic
target for better management of CRC patients.
Methods
Patient specimens
Colorectal cancer (CRC) patients specimens (n = 200)
were obtained during surgical tumor resection. The inves-
tigations were carried out after obtaining approval of
Institute Human Ethical Committee (IHEC approval #
65/11) and of Institutional Ethics Committees of All India
Institute of Medical Sciences Hospital (IEC approval #
IEC/NP-212/2010) and Mahatma Gandhi Medical College
Hospital (IEC approval # IEC/JPR/2012/0170) for provi-
ding tissue specimens and clinical data. Duly signed
consent forms were obtained from CRC patients enrolled
for the investigations. The available adjacent non-cancerous
tissue (ANCT) specimens were also collected. Resected
tumor specimens were collected in 10 % formalin (fixative)
and RNAlater for IHC and gene expression studies. All
tumor specimens were examined by two independent
pathologists. Control colon tissue samples (n = 40) were
obtained from the archives of the Department of Pathology,
to investigate the HSP70-2 expression.
Cell lines
Two colorectal cancer cell lines, COLO205 and HCT116
were procured from American Type Culture Collection
(ATCC, Manassas, VA) and were used within four weeks
of receiving the cell lines from ATCC. Both cell lines were
cultured in recommended medium under standard condi-
tions and were examined for mycoplasma contamination
by mycoplasma PCR detection kit (Applied Biological
Materials Inc., Richmond, Canada).
Analysis of HSP70-2 gene expression in cell lines and CRC
specimens
HSPA2 gene expression was examined using RT-PCR as
described earlier [4]. Briefly total RNA from CRC tissue
specimens and COLO205 and HCT116 cells was isolated
using RNeasy mini kit (Qiagen GmbH, Hilden, Germany)
according to manufacturer’s guidelines. Synthesis of cDNA
was carried out using High Capacity cDNA Reverse Tran-
scriptase kit (Applied biosystems, Foster city, CA). RT-
PCR was done using HSPA2 gene specific primers: for-
ward primer- 5’-CCTACTCGGACAACCAGAG-3’, reverse
primer- 5’-TCTCGTCTTCCACCGTCTG-3’. β-actin was
used as internal control using β-actin specific primers
(forward primer- 5’-ATCTGGCACCACACCTTCTACAAT
GAGCTGCG-3’ and reverse primer- 5’- CGTCATACTC
CTGCTTGCTGATCCACATCTGC-3’). Further, HSPA2
nucleotide sequence was confirmed by sub-cloning PCR
product in TOPO vector (Invitrogen, Life Technologies,
Carlsbad).
Immunohistochemistry (IHC)
HSP70-2 protein validation was performed by employing
IHC as described earlier [4]. Paraffin embedded blocks
were made from the tissue specimens and serial sections
of 4 μm were cut. Briefly, serial sections of CRC tissue
specimens and ANCT’s were subjected for HSP70-2
protein localization using anti-HSP70-2 antibody raised
in rabbit or control IgG [4]. Subsequently, sections were
incubated with horse radish peroxidase (HRP) conjugated
goat anti-rabbit IgG (Jackson ImmunoResearch Labora-
tories, West Grove, PA). The immunoreactivity was visu-
alized using chromogen, 0.05 % 3,3’-diaminobenzidine
[(DAB), Sigma Aldrich, St. Louis, MO]. The images of
tissue sections were captured using Nikon Eclipse E400
microscope (Nikon, Fukok, Japan) after staining with
hematoxylin, and mounted with DPX mountant (Sigma
Aldrich, St. Louis, MO).
HSP70-2 immuno-reactive score (IRS)
Two independent senior pathologists analyzed HSP70-2
immunoreactivity in CRC tissue sections by counting
five random fields (>500 cells) under 400x magnification
as described earlier [10]. CRC patients tissue specimens
were designated as positive for HSP70-2 expression
when >10 % of cells expressed HSP70-2 protein.
Western blotting, Indirect Immunofluorescence (IIF),
Fluorescence Activated Cell Sorting (FACS)
Protein expression of HSP70-2 was studied in CRC cells
by Western blotting as described earlier [4]. Cell lysate
(10 μg) was resolved on 10 % sodium dodecylsulphate-
polyacrylamide electrophoresis gel and was transferred
onto polyvinylidene fluoride (PVDF) membrane. Immuno-
reactivity was carried out by probing the membrane with
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rabbit anti-HSP70-2 antibody as primary antibody and
goat anti-rabbit HRP as secondary antibody and deve-
loped using enzyme linked chemiluminescence (Millipore
Immobilon Western Chemiluminescent HRP Substrate
(ECL), Millipore Corporation, Billerica, USA) reagent.
Further, localization of HSP70-2 protein in CRC cells
was demonstrated by IIF and FACS as described ear-
lier [11]. Cells were fixed using 3 % paraformaldehyde
and permeabilization was done using 0.05 % IGEPAL.
Co-localization of HSP70-2 with various sub-cellular
organelles was studied by probing the cells with anti-
bodies against organelles [endoplasmic reticulum marker
(calnexin, 6D195, sc-70481; Santa Cruz Biotechnology,
Santa Cruz, CA), golgi bodies marker (GM130 B-10,
sc-55591; Santa Cruz Biotechnology), mitochondria marker
(MTCO2, ab3298; Abcam) and nuclear envelope marker
(lamin A/C 636, sc-7292; Santa Cruz Biotechnology)]. The
images were captured using Carl Zeiss LSM 510 meta
confocal microscope (Germany). Co-localization quantifica-
tion analysis was carried out using AIM4.2 software [12] on
LSM Image Browser (Carl Zeiss, Germany). The results are
based on Mander’s coefficient of co-localization analyses
(M1), calculated from n = 20 cells from five examined areas
(regions of interest). For FACS analysis, cells were harvested
with scrapper and fixed with 0.4 % PFA for 10 min. Fixed
cells were then incubated with rabbit anti-HSP70-2 anti-
body for overnight at 4 °C followed by incubation with
secondary antibody. Also, in another experiment, cells were
harvested and incubated first with rabbit anti-HSP70-2
antibody for overnight at 4 °C prior to PFA fixation.
Unstained cells and cells stained with control IgG were
taken as control. Acquisition and analysis was done using
Cell QuestPro software on BD FACS CALIBUR (BD Bio-
sciences, California, USA).
Down regulation of HSP70-2 using plasmid mediated
gene silencing
HSP70-2 short hairpin RNA (shRNA) target plasmid
(shRNA1, CAT AAC GGT CCC GGC CTA TT; shRNA2,
GAG CGG TAC AAA TCG GAA GAT; shRNA3, CGG
CGA CAA ATC AGA GAA TGT; shRNA4, TTC GAC
GCC AAG AGG CTG CTG ATT) and Control shRNA
(NC shRNA, 5’-ATCTCGCTTGGGCGAGAGTAAG-3’)
were obtained from Super Array (Sure Silencing shRNA
Plasmid, Fredrick, Md). In our initial attempt, we trans-
fected both CRC cell lines (COLO205 and HCT116) with
all HSP70-2 shRNA targets and control NC shRNA to
examine the efficiency in ablating HSPA2 mRNA by quan-
titative PCR (qPCR) and HSP70-2 protein by Western
blotting as described earlier [4]. The CRC cells were trans-
fected in 6-well plates using lipofectamine reagent (Invi-
trogen, Life Technologies, Carlsbad, CA) as described
earlier [13]. Post 48 h transfection, CRC cells were har-
vested and cell lysates were prepared for analysis. Two
HSP70-2 shRNA targets which resulted in ablation of
HSP70-2 protein were used for all subsequent in vitro and
in vivo assays.
Cell growth, viability and colony formation assays
In order to examine the involvement of HSP70-2 expres-
sion with cellular proliferation, viability and colony forma-
tion ability, both CRC cells were transfected with two sets
of HSP70-2 shRNA (shRNA3 and shRNA4) or control
NC shRNA. The assays were performed as described ear-
lier [4]. For cellular proliferation, 1x104 HSP70-2 shRNA
(shRNA3 and shRNA4) and Control NC shRNA trans-
fected COLO205 and HCT116 cells were seeded per well
and counted at 24 h, 48 h and 72 h post transfection. For
cell viability assay, 5000 cells were seeded per well in
a 96-well plate. After 24 h, 48 h and 72 h of transfection, 3-
(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT, Sigma-Aldrich, St. Louis, MO) reagent was added to
the media and absorbance was measured at 534 nm after
4 h. For colony formation assay, cells were seeded at diffe-
rent density (400, 800 and 1200 cells). Colonies were
allowed to grow and counted after 10 days by staining with
toluidine blue.
Cell migration and invasion assay
Cellular migration and invasion are the key features of
cancer cells. Association of HSP70-2 protein expression in
cell migration and invasion of CRC cells was performed as
described earlier [4]. Briefly, 1x105 cells were counted and
seeded onto the 8 μm transwell inserts (BD Biosciences,
California, USA) in serum free media for migration assay.
For invasion assay inserts were coated with 5 mg/ml
matrigel (BD Biosciences, California, USA) and cells were
seeded similarly as for migration assay. The cells that
migrated or invaded through the insert in the lower cham-
ber were fixed with glutaraldehyde and stained with tolui-
dine blue and counted manually under microscope. The
images were captured using Nikon Eclipse E 400 micro-
scope (Nikon, Fukok, Japan).
Effect of plasmid driven gene silencing in human cancer
xenograft model
Total of 20 severely compromised immuno-deficient
(SCID) mice [National Institute of Immunology (NII),
National Institute of Health] of 6 weeks were kept under
sterile NII facility to undertake this study. All investiga-
tions in animals were carried out after obtaining ethical
clearance from Institute animal ethical committee (IAEC
approval #263/11). CRC cells (COLO205) were cultured
and counted. Five million cells were injected subcutane-
ously in the upper portion of hind legs. Animals were
monitored regularly and the development of tumor was
monitored using caliper, when the tumor volume reached
to 50 mm3, two groups of mice were made each having 8
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mice (Group I: control group and Group II: Experimental
group). Three injections, intratumoral schedule of thrice
weekly, of 50 μg Control NC shRNA or HSP70-2 shRNA4
were administered into group I or group II respectively.
The study was monitored for seven to eight weeks by
recording animal weight and measuring tumor volume as
described earlier [12]. Subsequently, all animals were
sacrificed and tumors were excised for studying HSP70-2
protein and proliferating cell nuclear antigen (PCNA)
expression.
Statistical analysis
Statistical data were analyzed using SPSS20.0 software
package (SPSS Inc. Chicago, IL, USA). The statistical
difference of HSP70-2 gene and protein expression in
different stages, grades, specimens with or without lymph
node involvement or metastasis were determined by
Mann Whitney U-test. Kruskal-Wallis test was performed
to find out the significant difference in HSP70-2 amongst
various stages and grades. Pearson’s χ2-squared test was
performed to find out the association of HSP70-2 expres-
sion in various stages and grades. A p value less than 0.05
was considered statistically significant.
Results
HSP70-2 gene is expressed in CRC cells and specimens
The HSPA2 gene expression was examined by RT-PCR in
CRC tissue specimens and CRC cells (COLO205 and
HCT116). RT-PCR data revealed that majority of CRC
patients (156 of 200; 78 %) were found positive for HSPA2
gene expression. Both CRC cell lines also expressed
HSP70-2 gene (Fig. 1a). However, no HSPA2 gene expres-
sion was detected in ANCT specimens. Among various
stages of CRC patient, 75 % of stage I, 78 % of stage II,
79 % of stage III and 76 % of stage IV showed HSPA2
gene expression (Table 1). Further based on histopatho-
logical grading, 79 % (56 of 71) of well differentiated and
79 % (81 of 102) of moderately differentiated specimens
revealed HSPA2 gene expression as compared to 70 %
(19 of 27) of poorly differentiated type. Further, our data
revealed that 121 of 155 (78 %) CRC patients with lymph
node involvement and 35 of 45 (78 %) CRC patients
without lymph node involvement expressed HSPA2 gene.
In addition, our data indicated that patients with negative
metastatic CRC revealed 117 of 149 (79 %) revealed
HSPA2 expression as compared to 39 of 51 (76 %)
patients with metastatic CRC.
CRC cells and patient specimens expressed HSP70-2
protein
We further validated HSPA2 gene expression for protein
expression in CRC cell lines and tissue specimens. Western
blotting analysis demonstrated HSP70-2 protein expression
in CRC cells (Fig. 1b). HSP70-2 protein expression was
examined by indirect immunofluorescence (IIF) in fixed
and permeabilized COLO205 and HCT116 cells, which
revealed that HSP70-2 protein was detected predominantly
in cytoplasm (Fig. 1c). In addition, HSP70-2 protein was
also detected in endoplasmic reticulum, golgi body and
mitochondria but did not co-localize with nuclear envelope
(Fig. 1c). The value of Mander's coefficient show 91.2 %
(M1: 0.912), 63.6 % (M1: 0.636) and 83.2 % (M1: 0.832) co-
localization of HSP70-2 in endoplasmic reticulum, Golgi
bodies and mitochondria respectively in COLO205 cells.
Similarly, 73.0 % (M1: 0.730), 66.0 % (M1: 0.660) and
69.4 % (M1: 0.694) co-localization of HSP70-2 in endoplas-
mic reticulum, Golgi bodies and mitochondria respectively
was observed in HCT116 cells. Flow cytometric analyses
revealed displacement shift (fluorescence) on X-axis (blue
color peak) in COLO205 and HCT116 cells when incu-
bated with anti-HSP70-2 antibody prior to PFA fixation as
well as in cells incubated with anti-HSP70-2 antibody post
PFA fixation (green peak) as compared to control IgG
stained (black color peak) and unstained (red color peak)
cells indicating surface localization of HSP70-2 protein
(Fig. 1d). Immunohistochemistry (IHC) analyses revealed
that majority of CRC patients 156 of 200 (78 %) were found
positive for endogenous HSP70-2 protein expression (Fig. 2
and Table 1). However, none of the ANCT specimen
demonstrated HSP70-2 protein expression (Fig. 2). CRC
specimens probed with control IgG failed to show any
immuno-reactivity against HSP70-2. Further, 75 % (6 of 8)
of stage I, 78 % (29 of 37) of stage II, 79 % (82 of 104) of
stage III and 76 % (39 of 51) of stage IV revealed HSP70-2
protein expression. In different CRC grades 56 of 71 (79 %)
well differentiated, 81 of 102 (79 %) moderately differenti-
ated, and 19 of 27 (70 %) poorly differentiated expressed
HSP70-2 protein. Our analysis showed that 78 % (121
of 155) of specimens with lymph node involvement and
78 % (35 of 45) of specimens without lymph node involve-
ment showed HSP70-2 protein expression. Our data also
indicated that 117 of 149 (79 %) patients with negative
metastatic CRC revealed HSP70-2 protein expression as
compared to 39 of 51 (76 %) patients with metastatic CRC.
Based on HSP70-2 immuno-reactivity score (IRS), we
compared the HSP70-2 IRS among stages and grades.
As depicted in Fig. 3, HSP70-2 IRS’s were 58.67 (mean)
± 2.29 (SE) in stage I, 52 ± 3.88 in stage II, 58.51 ± 2.13
in stage III and 56.59 ± 3.22 in stage IV. We also com-
pared early stage (stage I & II) and late stage (stage III &
IV) HSP70-2 IRS’s which were 53.14 ± 3.36 and 57.89 ±
1.77 respectively. Kruskal-Wallis test revealed no signifi-
cant difference among the various stages (p = 0.57).
Further, in well differentiated, moderately differentiated
and poorly differentiated HSP70-2 IRS’s were 58.52 ±
2.61, 52.95 ± 2.63 and 68.37 ± 2.08 respectively. A signi-
ficant difference was found between moderately differen-
tiated and poorly differentiated (p = 0.03) using the Mann
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Whitney U-test, however, no significant difference was
observed between well differentiated and moderately
differentiated (p = 0.39) or between well differentiated and
poorly differentiated (p = 0.09). Interestingly, significant
difference was observed among various grades (p = 0.008)
using the Kruskal-Wallis test. On the basis of lymph node
involvement in CRC specimens, HSP70-2 IRS was 57.89
± 1.77 in patients with lymph node involvement and
53.14 ± 3.36 in patients without lymph node involvement,
while with respect to the presence or absence of metasta-
sis, HSP70-2 IRS was 56.59 ± 3.21 in metastatic specimens
and 57.11 ± 1.83 in specimens with no metastasis.
We further grouped CRC specimens based on HSP70-
2 IRS, group I, low HSP70-2 IRS (<50 % tumor cells
expressing HSP70-2) and group II, high HSP70-2 IRS
(>50 % tumor cells expressing HSP70-2). Our results
indicated that 65 % of CRC patients revealed high
HSP70-2 IRS (69.42 ± 1.02) as compared to 35 % with
low HSP70-2 IRS (33.97 ± 1.09) which was significantly
different was observed among the groups (p < 0.0001) as
analyzed using Mann Whitney U-test, depicted in histo-
graph (Fig. 3).
Knockdown of HSP70-2 results in reduction of cellular
proliferation, cell viability and colony forming ability
Plasmid driven shRNA mediated gene silencing approach
was employed to ablate the HSP70-2 gene and protein by
four different HSP70-2 shRNA targets along with control
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Fig. 1 CRC patient specimens and cells express HSP70-2 mRNA and protein. a RT-PCR analysis shows HSP70-2 mRNA expression in stage I-IV, grades
WD, MD and PD and CRC cells (COLO205 and HCT 116). ANCT specimens failed to express HSP70-2 mRNA. Testis was used a positive control and
β-actin was used as a loading control. b Western blotting reveals HSP70-2 protein expression, COLO205 and HCT116 cells. c IIF analysis depicts
predominantly cytoplasmic localization; co-localization reveals HSP70-2 protein in endoplasmic reticulum, golgi bodies, mitochondria and plasma
membrane (yellowish-orange staining). No co-localization was seen with nuclear envelope. Co-localization of HSP70-2 in endoplasmic reticulum,
Golgi bodies and mitochondria in both COLO205 and HCT116 CRC cells was observed and quantified (see Methods) Histogram depicts average
percentage co-localization in n = 20 cells from five examined areas (regions of interest). Original magnification x630, objective x63. Scale bar: 10 μm.
d Flow cytometric analysis demonstrates the displacement shift of fluorescence (green color peak: depicts cells fixed with PFA prior to first antibody
incubation and blue color peak: depicts cells incubated first with primary antibody followed by PFA fixation) in COLO205 and HCT116 cells as
compared to control IgG stained (black color peak) and unstained (red color peak) cells. WD: well differentiated, MD: moderately differentiated
and PD: poorly differentiated
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NC shRNA. Quantitative PCR (qPCR) results revealed
that HSP70-2 shRNA3 and shRNA4 were most efficient in
down-regulating HSP70-2 gene in COLO205 (72 % and
78 %) and in HCT116 cells (75 % and 80 %) as compared
to control NC shRNA (Fig. 4a). Further, Western blotting
analysis post 48 h transfection showed maximum ablation
of HSP70-2 protein (Fig. 4b) with HSP70-2 shRNA3 and
shRNA4. Hence, for all subsequent in vitro assays, HSP70-
2 shRNA3 and shRNA4 were used along with control NC
shRNA. For cellular proliferation and cell viability assay,
CRC cells were transfected with HSP70-2 shRNA3 and
shRNA4 which resulted in significant reduction in cellular
Table 1 Clinicopathological characteristics of colorectal carcinoma patients and HSP70-2 gene and protein expression
Clinicopathological features RT-PCR (%) of tissue IHC (%) of tissue
All tumors 156/200 (78) 156/200 (78)
Adjacent normal cancerous tissues 0/160 (0) 0/160 (0)
Tumor stages
Stage I 6/8 (75) 6/8 (75)
Stage II 29/37 (79) 29/37 (79)
Early stages (I + II) 35/45 (78) 35/45 (78)
Stage III 82/104 (79) 82/104 (79)
Stage IV 39/51 (76) 39/51 (76)
Late stages (III + IV) 121/155 (78) 121/155 (78)
Histologic grades
Well differentiated 56/71 (79) 56/71 (79)
Moderately differentiated 81/102 (79) 81/102 (79)
Poorly differentiated 19/27 (70) 19/27 (70)
Lymph node involvement
Positive 121/155 (78) 121/155 (78)
Negative 35/45 (78) 35/45 (78)
Metastasis
Positive 39/51 (76) 39/51 (76)
Negative 117/149 (79) 117/149 (79)
Statistical analysis (p values of different test used in this study)
Clinicopathological features Mann-Whitney U-test Pearson’s χ2 test Kruskal-Wallis Test
RT-PCR/IHC RT-PCR/IHC RT-PCR/IHC
ANCT, malignancy 0.0001* 0.0001* -
Tumor Stage
I + II 0.554 0.835
II + III 0.152 0.952
III + IV 0.631 0.737
I + II & III + IV 0.202 0.967
I, II, III, and IV - 0.984 0.573
Histological Grade
WD, MD+ PD - 0.587 0.008*
WD +MD 0.388 0.932
WD + PD 0.09 0.375
MD + PD 0.03* 0.268
Lymph Node Positivity 0.202 0.967
Metastasis Positivity 0.859 0.760
IHC immunohistochemistry, MD moderately differentiated, PD poorly differentiated, WD well differentiated
*p < 0.05, statistically significant
Statistical analysis (p values of different test used in this study)
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growth of COLO205 with HSP70-2 shRNA3 (50 %; p <
0.01) and with HSP70-2 shRNA4 (56 %; p < 0.005) as com-
pared to control NC shRNA transfected cells (Fig. 4c).
Similarly significant cellular proliferation reduction was
observed in HCT116 with HSP70-2 shRNA3 (44 %; p <
0.005) and with HSP70-2 shRNA4 (56 %; p < 0.005) (Fig. 4c).
In addition, both shRNA targets also revealed significant
reduction in cell viability of CRC cell lines as examined by
MTT assay (Fig. 4d). Significant reduction in cell viability
was observed in COLO205 cells when transfected with
HSP70-2 shRNA3 (50 %, p < 0.0001) and HSP70-2 shRNA4
(55 %, p < 0.0001) as well as in HCT116 cells when
transfected with HSP70-2 shRNA3 (51 %, p < 0.0001) and
HSP70-2 shRNA4 (53 %, p < 0.0001) as compared to con-
trol NC shRNA. Colony forming ability was also reduced
significantly (p < 0.05) by 44-55 % (400–1200 cells) for
COLO205 cells whereas 44-63 % (400–1200 cells) reduc-























Normal 1 Normal 2 Normal 3 Normal 4
Fig. 2 CRC specimens express HSP70-2 protein. First panel shows the cytostructure of representative micrographs of stage I-IV CRC specimen sections
stained with H&E. Second panel shows chocolate brown reactivity in Stage I-IV CRC specimen sections probed with anti-HSP70-2 antibody. No
immuno-reactivity was observed in stage I-IV CRC specimen sections probed with control IgG antibody (Third panel). ANCT specimens failed to show
any immuno-reactivity probed with anti-HSP70-2 antibody (Fourth panel). Bottom most panel shows no HSP70-2 protein expression in representative
specimens obtained from healthy patients. Original magnification x200, objective x20. Scale bar: 100 μm
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Knockdown of HSP70-2 inhibits migration and invasion of
CRC cells
Role of HSP70-2 was investigated in migratory and inva-
sive ability that revealed significant inhibition in migra-
tion of COLO205 cells when transfected with HSP70-2
shRNA3 (66 %, p < 0.0001) and HSP70-2 shRNA4 (74 %,
p < 0.0001) as compared to control NC shRNA (Fig. 5a).
Similarly, significant reduction was observed in HCT116
cells when transfected with HSP70-2 shRNA3 (64 %, p <
0.001) and HSP70-2 shRNA4 (74 %, p < 0.0005, Fig. 5b)
as compared to control NC shRNA. To assess the invasive
ability of CRC cells, reconstituted basement membrane
(matrigel) was used. Our results revealed a significant
reduction of invasive ability (63 %; p < 0.005) with HSP70-
2 shRNA3 and (67 %; p < 0.0001) with HSP70-2 shRNA4
in COLO205 cells (Fig. 5a); (68 %; p < 0.001) with HSP70-
2 shRNA3 and (70 %; p < 0.0005) with HSP70-2 shRNA4
in HCT116 cells as compared to control NC shRNA
(Fig. 5b). Our gene silencing studies collectively suggests
that HSP70-2 may be involved in migration and invasion
of CRC cells.
HSP70-2 shRNA reduced tumor growth in human colon
cancer xenograft in mice
Our in vitro data indicated that ablation of HSP70-2
protein significantly reduced various malignant properties
of COLO205 cells which led us to investigate its effect on
COLO205 cell xenograft tumor growth in SCID mice.
Control group and experimental group mice were treated
with control NC shRNA or HSP70-2 shRNA4 and were
observed for 49 days. A representative photograph (Fig. 6a)
shows reduced tumor growth in HSP70-2 shRNA4 treated
group compared with control NC shRNA treated group.
The tumor volume of experimental group mice showed
a significant reduction (p < 0.0001) in tumor growth as
compared to mice administered with control NC shRNA
(Fig. 6b). As depicted in histograph, HSP70-2 shRNA4
treatment resulted in 78 % (p < 0.0001) decreased tumor
growth and 76 % (p < 0.0001) tumor weight at day 49
(Fig. 6c). Furthermore, the xenograft tumors were excised
and processed for Western blotting and immunohisto-
chemical staining for HSP70-2 protein expression. The









































































































Fig. 3 HSP70-2 Immunoreactive Score (IRS). Representative histogram depicts (a) HSP70-2 IRS of CRC specimens of stages I-IV and grades WD, MD
and PD. b HSP70-2 IRS of CRC specimens based on percentage of tumor cells expressing HSP70-2 (group I, <50 % cells expressing HSP70-2; group II,
>50 % cells expressing HSP70-2). c HSP70-2 IRS of early and late stage CRC specimens. WD: well differentiated, MD: moderately differentiated and PD:
poorly differentiated. *p < 0.005, statistically significant
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2 shRNA4 treated mice (75 %; p < 0.0001) compared with
mice treated with control NC shRNA (Fig. 6d and e).
Serial tumor sections were also probed for proliferating
cell nuclear antigen (PCNA) expression. Our data revealed
that there was significant reduction of PCNA expression
(75 %; p < 0.0001) in tumors treated with HSP70-2 shRNA4
as compared with control NC shRNA shown in Fig. 6d
and e. These results suggest that HSP70-2 may be a
molecular target for novel cancer treatment.
Discussion
Colorectal cancer (CRC) is one of the most common
causes of cancer related morbidity in both men and
women worldwide [14]. It has been well documented that
CRC patients diagnosed at early stages have better treat-
ment options with increased survival rate. Therefore, there
is a need to identify a tumor marker for early detection
and diagnosis. At present, carcinoembryonic antigen
(CEA) and carbohydrate antigen (CA19-9) are found to be
elevated during late stages CRC when metastasis has
already began and are being used in clinical setup with
limited efficacy [15]. Cancer testis (CT) antigens are a
unique class of proteins that are expressed only in testis
during spermatogenesis and have been reported in various
malignancies [9]. Only few CT antigens namely sperm
associated antigen 9 (SPAG9) [13], OY-TES-1 [16], New
York-Esophageal (NY-ESO-1) [17], melanoma-associated
antigen 3 (MAGE-A3) [18] and testis specific protease
(TSP50) [19] association have been reported in CRC. How-
ever, none of these antigens are in clinical practice for CRC
detection and diagnosis. Therefore, there is an urgent need
to identify a target molecule for early detection and diag-
nosis and which may also be useful as a therapeutic target
for CRC.
Fig. 4 HSP70-2 gene silencing retards cellular growth, cell viability, colony forming ability of CRC cells. a Quantitative PCR shows significantly reduced
expression of HSP70-2 mRNA in COLO205 and HCT116 cells when transfected with HSP70-2 shRNA3 and shRNA4 as compared to control NC shRNA
or HSP70-2 shRNA1, 2. b HSP70-2 shRNA3 & shRNA4 transfected COLO205 and HCT116 cells show significant HSP70-2 protein ablation as compared
to control NC shRNA or shRNA1, 2. β-actin was used as a loading control. c Cellular proliferation assay demonstrates the significant reduced cellular
growth of COLO205 and HCT116 transfected with HSP70-2 shRNA3 and shRNA4 cells at 24 h, 48 h and 72 h. d Cell viability as analyzed by MTT assay
depicts the significant reduction of viable cells when transfected with HSP70-2 shRNA3 and shRNA4. e Colony forming ability was significantly reduced
when COLO205 and HCT116 cells were transfected with HSP70-2 shRNA3 and shRNA4. f Representative images of the colony forming ability of
HSP70-2 shRNA3 and shRNA4 transfected COLO205 and HCT116 cells as compared to control NC transfected cells. *p < 0.0001, statistically significant.
All the results are an average of triplicates (n = 3) and the experiments were repeated twice
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HSP70-2, a new member of CT antigens family, is
expressed in various malignancies [4, 19, 20]. In the
present investigation total of 200 CRC clinical specimens
were examined for HSPA2 gene expression which revealed
that majority of the patient specimens (78 %) were found
positive for HSP70-2 gene expression irrespective of vari-
ous stages and grades. It is important to mention that
HSP70-2 gene expression in early stages (I & II) was
detected in 78 % of CRC patients. Our laboratory has
earlier reported SPAG9 gene expression in 74 % of CRC
patients [13]. OY-TES-1 gene expression was found in
73.3 % of CRC patients [16]. Earlier, MAGE family gene
expression was also reported in CRC patients which
revealed that 11.6 % of MAGE-1, 27.3 % of MAGE-3 and
22.3 % of MAGE-4 [21]. The same group also reported
SSX family gene expression which showed 5 % of SSX-1,
2.5 % of SSX-2 and 2.5 % of SSX-4 in CRC patients [21].
Yet another well studied CT antigen NY-ESO-1 gene
expression was only reported in 9.9 % of CRC patients





































































































































Fig. 5 Knockdown of HSP70-2 inhibited migration and invasion of CRC cells. a Micrographs depict the reduced migratory and invasive ability of
COLO205 post transfection with HSP70-2 shRNA3 and shRNA4 as compare to control NC shRNA. b Representative micrograph shows reduction
in migration and invasion of HCT116 cells post transfection with HSP70-2 shRNA3 and shRNA4 compare to control NC shRNA. Histogram shows
significant reduction in migration and invasion of COLO205 and HCT116 cells. *p < 0.0001, statistically significant, Original magnification x100,
objective x10. All the results are an average of triplicates (n = 3) and the experiments were repeated twice
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gene expression was found in majority of CRC patients
which needs to be further validated in large number of
specimens.
Recently, differential gene expression profiles have
resulted in identification of various genes which are
expressed in cancer cells only. However, most of these
genes have not been validated for protein expression,
hence; have not been put in clinical practice [22]. There-
fore, in this context, immunohistochemical analysis was
performed to validate HSP70-2 gene expression and
interestingly our data documented that there was no
discrepancy found between the HSP70-2 gene and protein
expression. HSP70-2 protein was found to be expressed in
78 % of CRC patients. As against gene expression of
various CT antigens, protein expression of only few CT
antigens has been studied in CRC. SPAG9 protein has
been shown to be expressed in 74 % of CRC patients.
OY-TES-1 protein was detected only in 43.3 % (26/60)
CRC patients [16], whereas, NY-ESO-1 and MAGE-A3
protein is expressed in upto 10 % and 8 % respectively in
CRC patients [17, 18]. Yet another testis specific protease
(TSP50) was shown to be associated in 68 % of CRC
patients. Further, TSP50 expression was not shown to be
significantly associated with CRC and the clinicopatholo-
gical features [19].
CRC disease progression involves tumor growth, migra-
tion and invasion of cancer cells to distant sites resulting
in metastasis [23]. It was intriguing that HSP70-2 gene
and expression was detected in the majority of early





















































































































































Fig. 6 HSP70-2 gene silencing resulted in reduced tumor growth of COLO205 xenograft. a Representative images of resected tumor show significant
reduction in tumor size treated with HSP70-2 shRNA4 as compared to control NC shRNA treated tumor. b Graph represents reduced tumor growth
in HSP70-2 shRNA4 treated mice as compared to control NC shRNA treated mice. c Histogram depicts decreased tumor weight in HSP70-2 shRNA4
treated mice as compared to control NC shRNA treated mice. d Western Blot analysis shows reduced HSP70-2 protein and PCNA expression in
HSP70-2 shRNA4 treated mice as compared to control NC shRNA treated mice. β-actin was used as a loading control. e IHC analysis of tumor sections
show reduced HSP70-2 (middle panel) and PCNA (right panel) expression in HSP70-2 shRNA4 treated mice as compared to control NC shRNA treated
mice. Left panel shows cytostructure by H&E staining. Representative histogram shows significant reduced HSP70-2 and PCNA expression in HSP70-2
shRNA4 treated mice as compared to control NC shRNA treated mice. *p < 0.0001, statistically significant. Original magnification x200, objective x20.
Scale bar: 100 μm
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us to further investigate the association of HSP70-2 gene
and protein in CRC (COLO205 and HCT 116) in in-vitro
and in-vivo model. To the best of our knowledge, this is
the first study reporting the role of HSP70-2 in CRC
specimens and with various malignant properties of CRC
cells. Plasmid driven gene silencing approach revealed
reduced cellular proliferation, cell viability, colony forming
ability, migratory and invasive abilities of COLO205 and
HCT 116 cells. In in-vivo human tumor xenograft mouse
model HSP70-2 shRNA4 treated animals showed reduced
tumor growth. An earlier study demonstrated HSP70-2
gene expression in primary and metastatic breast cancer
in 8 clinical specimens only [20]. We recently demonstrated
that HSP70-2 gene silencing inhibited the cellular growth
and cell motility in urothelial bladder [4] and cervical
cancer [5]. The underlying mechanisms by which HSP70-2
gene and protein silencing alters the malignant properties
of CRC are yet not clear. Hence, further studies are
warranted to understand the mechanisms through which
HSP70-2 is involved in CRC carcinogenesis.
Collectively, our data shows that HSP70-2 is significantly
associated with CRC irrespective of its stages and grades.
The HSP70-2 gene and protein ablation in CRC cells
results in significant reduction of malignant properties. Our
study suggests HSP70-2 expression is associated with CRC
and may be a putative molecule for early detection and
diagnosis and for developing a novel therapeutic target.
Conclusion
In summary, HSP70-2 plays an important role in various
stages and different grades of CRC patients. In addition,
HSP70-2 is involved in acquiring various malignant
properties of CRC cells and may lead to the develop-
ment of potential therapeutic target for CRC treatment.
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